A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120
Open Access
- 1 July 2008
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (13) , 6359-6368
- https://doi.org/10.1128/jvi.00293-08
Abstract
The glycan shield of human immunodeficiency virus type 1 (HIV-1) gp120 contributes to viral evasion from humoral immune responses. However, the shield is recognized by the HIV-1 broadly neutralizing antibody (Ab), 2G12, at a relatively conserved cluster of oligomannose glycans. The discovery of 2G12 raises the possibility that a carbohydrate immunogen may be developed that could elicit 2G12-like neutralizing Abs and contribute to an AIDS vaccine. We have previously dissected the fine specificity of 2G12 and reported that the synthetic tetramannoside (Man 4 ) that corresponds to the D1 arm of Man 9 GlcNAc 2 inhibits 2G12 binding to gp120 as efficiently as Man 9 GlcNAc 2 itself, indicating the potential use of Man 4 as a building block for creating immunogens. Here, we describe the development of neoglycoconjugates displaying variable copy numbers of Man 4 on bovine serum albumin (BSA) molecules by conjugation to Lys residues. The increased valency enhances the apparent affinity of 2G12 for Man 4 up to a limit which is achieved at ∼10 copies per BSA molecule, beyond which no further enhancement is observed. Immunization of rabbits with BSA-(Man 4 ) 14 elicits significant serum Ab titers to Man 4 . However, these Abs are unable to bind gp120. Further analysis reveals that the elicited Abs bind a variety of unbranched and, to a lesser extent, branched Man 9 derivatives but not natural N -linked oligomannose containing the chitobiose core. These results suggest that Abs can be readily elicited against the D1 arm; however, potential differences in the presentation of Man 4 on neoglycoconjugates, compared to glycoproteins, poses challenges for eliciting anti-mannose Abs capable of cross-reacting with gp120 and HIV-1.Keywords
This publication has 75 references indexed in Scilit:
- Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early InfectionJournal of Virology, 2007
- Broad HIV-1 neutralization mediated by CD4-binding site antibodiesNature Medicine, 2007
- Fully Synthetic Carbohydrate HIV Antigens Designed on the Logic of the 2G12 AntibodyJournal of the American Chemical Society, 2007
- Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationProceedings of the National Academy of Sciences, 2007
- Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex In SituPLoS Pathogens, 2006
- Toward Fully Synthetic Carbohydrate-Based HIV Antigen Design: On the Critical Role of BivalencyJournal of the American Chemical Society, 2004
- Covalent Display of Oligosaccharide Arrays in Microtiter PlatesJournal of the American Chemical Society, 2004
- Complete Protection of Neonatal Rhesus Macaques against Oral Exposure to Pathogenic Simian‐Human Immunodeficiency Virus by Human Anti‐HIV Monoclonal AntibodiesThe Journal of Infectious Diseases, 2004
- Reactivity‐Based One‐Pot Synthesis of Oligomannoses: Defining Antigens Recognized by 2G12, a Broadly Neutralizing Anti‐HIV‐1 AntibodyAngewandte Chemie International Edition in English, 2004
- Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial LibrariesJournal of Molecular Biology, 1993